Bupropion
Bupropion
Klass : C
Visa all info
Skriv ut
Kontakta oss
Produkter
Visa alla produkter
Bupropion Accord, Bupropion Bluefish, Bupropion Ebb, Bupropion Orion, ......
Bupropion Accord, Bupropion Bluefish, Bupropion Ebb, Bupropion Orion, Bupropion Paranova, Bupropion Pharmachim, Bupropion Sandoz, Bupropion Teva, Bupropion Zentiva, Bupropion hydrochloride, Mysimba, Voxra, WELLBUTRIN, Wellbutrin, ZybanATC-koder
A08AA62, N06AX12
A08AA62, N06AX12Substanser
bupropion, bupropionhydroklorid
bupropion, bupropionhydrokloridSammanfattning
Kvinnor kan ha fler biverkningar i form av abstinens och trötthet relaterat till rökstopp vid behandling med bupropion. De flesta studier visar att effekten av bupropionbehandling vid rökavvänjning är lika hos kvinnor och män. Inga könsskillnader i bupropions effekt vid depression har visats.
Kvinnor kan ha fler biverkningar i form av abstinens och trötthet relaterat till rökstopp vid behandling med bupropion. De flesta studier visar att effekten av bupropionbehandling vid rökavvänjning är lika hos kvinnor och män. Inga könsskillnader i bupropions effekt vid depression har visats.Background
There may be different predictors in smoking cessation success between men and women. Predictors for success in smoking cessation in women are higher education [1, 2], no e-cigarette use, early smoking initiation, and low-to-moderate alcohol consumption [1]. Weight gain in women is a predictor for failed smoking cessation [3]. In men, predictors for success are no use of nicotine replacement, current employment, family opinion on smoking [1], no previous depression, and a relative lack of anxiousness, irritability and hopelessness during quitting [2]. Women have greater motivation to quit smoking, according to some studies [4]. Visa hela bakgrundstexten
Depression is almost twice as common in women as in men [5]. Women have an earlier age of onset and increased duration of depressive episodes. The mechanisms behind these sex differences may be due to several factors such as differences in neurobiology [6, 7], inflammatory markers, diagnostic tools, or health seeking behaviour [8, 9]. Although depression is more prevalent in women, most preclinical studies on depression have used male animals [6] and the clin......
Försäljning på recept
Visa hela försäljning på recept
Fler kvinnor än män hämtade ut tabletter innehållande bupropion (ATC-kod N06AX12) på recept i Sverige år 2023, totalt 39 860 kvinnor och 25 386 män. Det motsvarar 7,6 respektive 4,8 personer per tusen invånare. Andelen som hämtat ut läkemedel var högst i åldersgruppen 25–49 år hos båda könen. I genomsnitt var tabletter innehållande bupropion 1,6 gånger vanligare hos kvinnor [37]. Bupropion används vid olika indikationer och då saknas könsuppdelade användningsdata. Fler kvinnor hämtade ut tabletter innehållande kombination av bupropion och naltrexen (ATC-kod A08AA62) på recept i Sverige år 2023, totalt 3 319 kvinnor och 822 män. Det motsvarar 0,6 respektive 0,2 personer per tusen invånare. Andelen som hämtat ut läkemedel var högst i åldersgruppen 35–59 år hos båda könen. I genomsnitt var tabletter innehållande kombination av bupropion och naltrexon 4,6 gånger vanligare hos kvinnor [37].
Referenser
Visa referenser
Manns A, Torregrossa H, Mahdjoub S, Gomajee R, Melchior M, El-Khoury Lesueur F. Do Determinants of Smoking Cessation and Relapse Differ between Men and Women? Data from a French National Study. Subst Use Misuse. 2024;59(2):167-176.
Swan GE, Javitz HS, Jack LM, Curry SJ, McAfee T. Heterogeneity in 12-month outcome among female and male smokers. Addiction. 2004;99:237-50.
Kuo CW, Lin CF, Chen CY, Wang RH, Chou CY, Cheng HJ et al. Body-Weight Gain in Women During Smoking Cessation Is a Sex-Specific Predictor of 6-Month Abstinence: A Retrospective Cohort Study. Front Public Health. 2022;10:872220.
Cropsey KL, Leventhal AM, Stevens EN, Trent LR, Clark CB, Lahti AC et al. Expectancies for the effectiveness of different tobacco interventions account for racial and gender differences in motivation to quit and abstinence self-efficacy. Nicotine Tob Res. 2014;16:1174-82.
Nationella riktlinjer för vård vid depression och ångestsyndrom 2021. Socialstyrelsen [www]. Socialstyrelsen. [updated 2021-04-01, cited 2021-05-14].
LeGates TA, Kvarta MD, Thompson SM. Sex differences in antidepressant efficacy. Neuropsychopharmacology. 2019;44(1):140-154.
Sramek JJ, Murphy MF, Cutler NR. Sex differences in the psychopharmacological treatment of depression. Dialogues Clin Neurosci. 2016;18(4):447-457.
Kerber CS, Dyck MJ, Culp KR, Buckwalter K. Antidepressant treatment of depression in rural nursing home residents. Issues Ment Health Nurs. 2008;29(9):959-73.
Labaka A, Goñi-Balentziaga O, Lebeña A, Pérez-Tejada J. Biological Sex Differences in Depression: A Systematic Review. Biol Res Nurs. 2018;20(4):383-392.
Hsyu PH, Singh A, Giargiari TD, Dunn JA, Ascher JA, Johnston JA. Pharmacokinetics of bupropion and its metabolites in cigarette smokers versus nonsmokers. J Clin Pharmacol. 1997;37:737-43.
Martindale: The Complete Drug Reference. Pharmaceutical Press.
Stewart JJ, Berkel HJ, Parish RC, Simar MR, Syed A, Bocchini JA et al. Single-dose pharmacokinetics of bupropion in adolescents: effects of smoking status and gender. J Clin Pharmacol. 2001;41:770-8.
Wellbutrin SR (bupropion). DailyMed [www]. [updated 2024-04-22, cited 2024-05-23].
Lamba V, Lamba J, Yasuda K, Strom S, Davila J, Hancock ML et al. Hepatic CYP2B6 expression: gender and ethnic differences and relationship to CYP2B6 genotype and CAR (constitutive androstane receptor) expression. J Pharmacol Exp Ther. 2003;307(3):906-22.
Ilic K, Hawke RL, Thirumaran RK, Schuetz EG, Hull JH, Kashuba AD et al. The influence of sex, ethnicity, and CYP2B6 genotype on bupropion metabolism as an index of hepatic CYP2B6 activity in humans. Drug Metab Dispos. 2013;41(3):575-81.
Zyban (bupropion). Summary of Product Characteristics. Swedish Medical Products Agency [updated 2024-04-04, citeid 2024-05-23].
Collins BN, Wileyto EP, Patterson F, Rukstalis M, Audrain-McGovern J, Kaufmann V et al. Gender differences in smoking cessation in a placebo-controlled trial of bupropion with behavioral counseling. Nicotine Tob Res. 2004;6:27-37.
Hall SM, Humfleet GL, Muñoz RF, Reus VI, Robbins JA, Prochaska JJ. Extended treatment of older cigarette smokers. Addiction. 2009;104:1043-52.
Hoving EF, Mudde AN, de Vries H. Predictors of smoking relapse in a sample of Dutch adult smokers; the roles of gender and action plans. Addict Behav. 2006;31:1177-89.
Cinciripini PM, Robinson JD, Karam-Hage M, Minnix JA, Lam C, Versace F et al. Effects of varenicline and bupropion sustained-release use plus intensive smoking cessation counseling on prolonged abstinence from smoking and on depression, negative affect, and other symptoms of nicotine withdrawal. JAMA Psychiatry. 2013;70:522-33.
Gonzales D, Rennard SI, Nides M, Oncken C, Azoulay S, Billing CB et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA. 2006;296:47-55.
Aubin HJ, Lebargy F, Berlin I, Bidaut-Mazel C, Chemali-Hudry J, Lagrue G. Efficacy of bupropion and predictors of successful outcome in a sample of French smokers: a randomized placebo-controlled trial. Addiction. 2004;99:1206-18.
Japuntich SJ, Leventhal AM, Piper ME, Bolt DM, Roberts LJ, Fiore MC et al. Smoker characteristics and smoking-cessation milestones. Am J Prev Med. 2011;40:286-94.
Iliceto P, Fino E, Pasquariello S, D'Angelo Di Paola ME, Enea D. Predictors of success in smoking cessation among Italian adults motivated to quit. J Subst Abuse Treat. ;44:534-40.
Rose JE, Behm FM. Combination treatment with varenicline and bupropion in an adaptive smoking cessation paradigm. Am J Psychiatry. 2014;171:1199-205.
Papakostas GI, Kornstein SG, Clayton AH, Soares CN, Hallett LA, Krishen A et al. Relative antidepressant efficacy of bupropion and the selective serotonin reuptake inhibitors in major depressive disorder: gender-age interactions. Int Clin Psychopharmacol. 2007;22(4):226-9.
Liu X, Li R, Lanza ST, Vasilenko SA, Piper M. Understanding the role of cessation fatigue in the smoking cessation process. Drug Alcohol Depend. 2013;133:548-55.
Gunnell D, Irvine D, Wise L, Davies C, Martin RM. Varenicline and suicidal behaviour: a cohort study based on data from the General Practice Research Database. BMJ. 2009;339:b3805.
Svanström H, Pasternak B, Hviid A. Use of varenicline for smoking cessation and risk of serious cardiovascular events: nationwide cohort study. BMJ. 2012;345:e7176.
Kasza KA, Hyland AJ, Borland R, McNeill AD, Bansal-Travers M, Fix BV et al. Effectiveness of stop-smoking medications: findings from the International Tobacco Control (ITC) Four Country Survey. Addiction. 2013;108:193-202.
Cooper J, Borland R, Yong HH. Australian smokers increasingly use help to quit, but number of attempts remains stable: findings from the International Tobacco Control Study 2002-09. Aust N Z J Public Health. 2011;35:368-76.
Huang Y, Britton J, Hubbard R, Lewis S. Who receives prescriptions for smoking cessation medications? An association rule mining analysis using a large primary care database. Tob Control. 2013;22:274-9.
Kotz D, Fidler J, West R. Factors associated with the use of aids to cessation in English smokers. Addiction. 2009;104:1403-10.
Thomas KH, Martin RM, Davies NM, Metcalfe C, Windmeijer F, Gunnell D. Smoking cessation treatment and risk of depression, suicide, and self harm in the Clinical Practice Research Datalink: prospective cohort study. BMJ. 2013;347:f5704.
Schwalsberger K, Reininghaus B, Reiter A, Dalkner N, Fleischmann E, Fellendorf F et al. Sex-Related Differences in the Pharmacological Treatment of Major Depression - Are Women and Men Treated Differently?. Psychiatr Danub. 2022;34(2):219-228.
Seifert J, Führmann F, Reinhard MA, Engel RR, Bernegger X, Bleich S et al. Sex differences in pharmacological treatment of major depressive disorder: results from the AMSP pharmacovigilance program from 2001 to 2017. J Neural Transm (Vienna). 2021;128(6):827-843.
Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2023 [cited 2024-03-06.]
- Manns A, Torregrossa H, Mahdjoub S, Gomajee R, Melchior M, El-Khoury Lesueur F. Do Determinants of Smoking Cessation and Relapse Differ between Men and Women? Data from a French National Study. Subst Use Misuse. 2024;59(2):167-176.
- Swan GE, Javitz HS, Jack LM, Curry SJ, McAfee T. Heterogeneity in 12-month outcome among female and male smokers. Addiction. 2004;99:237-50.
- Kuo CW, Lin CF, Chen CY, Wang RH, Chou CY, Cheng HJ et al. Body-Weight Gain in Women During Smoking Cessation Is a Sex-Specific Predictor of 6-Month Abstinence: A Retrospective Cohort Study. Front Public Health. 2022;10:872220.
- Cropsey KL, Leventhal AM, Stevens EN, Trent LR, Clark CB, Lahti AC et al. Expectancies for the effectiveness of different tobacco interventions account for racial and gender differences in motivation to quit and abstinence self-efficacy. Nicotine Tob Res. 2014;16:1174-82.
- Nationella riktlinjer för vård vid depression och ångestsyndrom 2021. Socialstyrelsen [www]. Socialstyrelsen. [updated 2021-04-01, cited 2021-05-14].
- LeGates TA, Kvarta MD, Thompson SM. Sex differences in antidepressant efficacy. Neuropsychopharmacology. 2019;44(1):140-154.
- Sramek JJ, Murphy MF, Cutler NR. Sex differences in the psychopharmacological treatment of depression. Dialogues Clin Neurosci. 2016;18(4):447-457.
- Kerber CS, Dyck MJ, Culp KR, Buckwalter K. Antidepressant treatment of depression in rural nursing home residents. Issues Ment Health Nurs. 2008;29(9):959-73.
- Labaka A, Goñi-Balentziaga O, Lebeña A, Pérez-Tejada J. Biological Sex Differences in Depression: A Systematic Review. Biol Res Nurs. 2018;20(4):383-392.
- Hsyu PH, Singh A, Giargiari TD, Dunn JA, Ascher JA, Johnston JA. Pharmacokinetics of bupropion and its metabolites in cigarette smokers versus nonsmokers. J Clin Pharmacol. 1997;37:737-43.
- Martindale: The Complete Drug Reference. Pharmaceutical Press.
- Stewart JJ, Berkel HJ, Parish RC, Simar MR, Syed A, Bocchini JA et al. Single-dose pharmacokinetics of bupropion in adolescents: effects of smoking status and gender. J Clin Pharmacol. 2001;41:770-8.
- Wellbutrin SR (bupropion). DailyMed [www]. [updated 2024-04-22, cited 2024-05-23].
- Lamba V, Lamba J, Yasuda K, Strom S, Davila J, Hancock ML et al. Hepatic CYP2B6 expression: gender and ethnic differences and relationship to CYP2B6 genotype and CAR (constitutive androstane receptor) expression. J Pharmacol Exp Ther. 2003;307(3):906-22.
- Ilic K, Hawke RL, Thirumaran RK, Schuetz EG, Hull JH, Kashuba AD et al. The influence of sex, ethnicity, and CYP2B6 genotype on bupropion metabolism as an index of hepatic CYP2B6 activity in humans. Drug Metab Dispos. 2013;41(3):575-81.
- Zyban (bupropion). Summary of Product Characteristics. Swedish Medical Products Agency [updated 2024-04-04, citeid 2024-05-23].
- Collins BN, Wileyto EP, Patterson F, Rukstalis M, Audrain-McGovern J, Kaufmann V et al. Gender differences in smoking cessation in a placebo-controlled trial of bupropion with behavioral counseling. Nicotine Tob Res. 2004;6:27-37.
- Hall SM, Humfleet GL, Muñoz RF, Reus VI, Robbins JA, Prochaska JJ. Extended treatment of older cigarette smokers. Addiction. 2009;104:1043-52.
- Hoving EF, Mudde AN, de Vries H. Predictors of smoking relapse in a sample of Dutch adult smokers; the roles of gender and action plans. Addict Behav. 2006;31:1177-89.
- Cinciripini PM, Robinson JD, Karam-Hage M, Minnix JA, Lam C, Versace F et al. Effects of varenicline and bupropion sustained-release use plus intensive smoking cessation counseling on prolonged abstinence from smoking and on depression, negative affect, and other symptoms of nicotine withdrawal. JAMA Psychiatry. 2013;70:522-33.
- Gonzales D, Rennard SI, Nides M, Oncken C, Azoulay S, Billing CB et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA. 2006;296:47-55.
- Aubin HJ, Lebargy F, Berlin I, Bidaut-Mazel C, Chemali-Hudry J, Lagrue G. Efficacy of bupropion and predictors of successful outcome in a sample of French smokers: a randomized placebo-controlled trial. Addiction. 2004;99:1206-18.
- Japuntich SJ, Leventhal AM, Piper ME, Bolt DM, Roberts LJ, Fiore MC et al. Smoker characteristics and smoking-cessation milestones. Am J Prev Med. 2011;40:286-94.
- Iliceto P, Fino E, Pasquariello S, D'Angelo Di Paola ME, Enea D. Predictors of success in smoking cessation among Italian adults motivated to quit. J Subst Abuse Treat. ;44:534-40.
- Rose JE, Behm FM. Combination treatment with varenicline and bupropion in an adaptive smoking cessation paradigm. Am J Psychiatry. 2014;171:1199-205.
- Papakostas GI, Kornstein SG, Clayton AH, Soares CN, Hallett LA, Krishen A et al. Relative antidepressant efficacy of bupropion and the selective serotonin reuptake inhibitors in major depressive disorder: gender-age interactions. Int Clin Psychopharmacol. 2007;22(4):226-9.
- Liu X, Li R, Lanza ST, Vasilenko SA, Piper M. Understanding the role of cessation fatigue in the smoking cessation process. Drug Alcohol Depend. 2013;133:548-55.
- Gunnell D, Irvine D, Wise L, Davies C, Martin RM. Varenicline and suicidal behaviour: a cohort study based on data from the General Practice Research Database. BMJ. 2009;339:b3805.
- Svanström H, Pasternak B, Hviid A. Use of varenicline for smoking cessation and risk of serious cardiovascular events: nationwide cohort study. BMJ. 2012;345:e7176.
- Kasza KA, Hyland AJ, Borland R, McNeill AD, Bansal-Travers M, Fix BV et al. Effectiveness of stop-smoking medications: findings from the International Tobacco Control (ITC) Four Country Survey. Addiction. 2013;108:193-202.
- Cooper J, Borland R, Yong HH. Australian smokers increasingly use help to quit, but number of attempts remains stable: findings from the International Tobacco Control Study 2002-09. Aust N Z J Public Health. 2011;35:368-76.
- Huang Y, Britton J, Hubbard R, Lewis S. Who receives prescriptions for smoking cessation medications? An association rule mining analysis using a large primary care database. Tob Control. 2013;22:274-9.
- Kotz D, Fidler J, West R. Factors associated with the use of aids to cessation in English smokers. Addiction. 2009;104:1403-10.
- Thomas KH, Martin RM, Davies NM, Metcalfe C, Windmeijer F, Gunnell D. Smoking cessation treatment and risk of depression, suicide, and self harm in the Clinical Practice Research Datalink: prospective cohort study. BMJ. 2013;347:f5704.
- Schwalsberger K, Reininghaus B, Reiter A, Dalkner N, Fleischmann E, Fellendorf F et al. Sex-Related Differences in the Pharmacological Treatment of Major Depression - Are Women and Men Treated Differently?. Psychiatr Danub. 2022;34(2):219-228.
- Seifert J, Führmann F, Reinhard MA, Engel RR, Bernegger X, Bleich S et al. Sex differences in pharmacological treatment of major depressive disorder: results from the AMSP pharmacovigilance program from 2001 to 2017. J Neural Transm (Vienna). 2021;128(6):827-843.
- Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2023 [cited 2024-03-06.]
Uppdaterat
Litteratursökningsdatum: 5/23/2024
Litteratursökningsdatum: 5/23/2024Fasstexter
Visa fasstexter
Se även
Vareniklin